Improvement in depressive symptoms by time point and treatment group.
REMISSION
Change from baseline in (The percentages of patients who achieved HAMD-17 response in the zuranolone+ADT and placebo+ADT groups were 53.4% and 49.2%, respectively, at D15 (odds ratio [OR] [95% CI], 1.15 [0.78, 1.69]; In the zuranolone+ADT and placebo+ADT groups, respectively, the proportions of patients with HAMD-17 remission were 29.1% and 21.8% at D15 (OR [95% CI], 1.41 [0.89, 2.24]; 